

## Treatment Appraisal: Decision Summary

Date	16 <sup>th</sup> August 2011				
Appraisal	Collagenase (Xiapex®) for Dupuytren's contracture				
Details	The North East Treatment Advisory Group considered the use of collagenase (Xiapex®) within its licensed indication for the treatment of Dupuytren's contracture and as a potential substitute for established surgical interventions.				
Recommendation	<p><b>The North East Treatment Advisory Group does not recommend collagenase (Xiapex®) for Dupuytren's contracture.</b></p> <p>The group was concerned about the absence of a direct clinical comparison with established treatment options such as surgery, and uncertainty regarding patient numbers and treatment costs.</p>				
Clinical evidence summary	The group noted the clinical evidence base supporting the use of collagenase for the treatment of Dupuytren's contracture however the group was disappointed by the absence of a direct randomised comparison with established treatment options. In the absence of such a comparison it was felt that the relative clinical efficacy and safety was not established.				
Cost analysis summary	The group noted the high purchase cost of collagenase (Xiapex®) but acknowledged the potential for savings compared with existing surgical treatment options. The group noted considerable uncertainties regarding use of collagenase relating to; the number of injections and associated clinical appointments, potential off-set costs relating to surgical interventions and associated healthcare utilisation, and the actual number of patients who would receive treatment.				
Financial impact		Estimated number of surgical cases*	Estimated number of Xiapex® cases (one-third of surgical cases)	Estimated cost of Xiapex® (mean two injections per patient)	Estimated saving against day-case palmar fasciectomy**
	Primary Care Organisation				
	NHS Durham & Darlington	148	50	£97,200	£32,400
	NHS North of Tyne	191	64	£124,416	£41,500
	NHS South of Tyne	160	54	£104,976	£35,000
	NHS Tees	126	42	£81,648	£27,200
PbR: Excluded	NHS North East	625	210	£408,240	£136,000
	* Excluding revisions and amputations. ** Adjusted to allow for surgical revision in 7% of cases.				
Further research or information					

Not to be used for commercial or marketing purposes